Board of Directors | Management | Investors
______________________________________________________________________________________________
Dr. McCarthy has more than 15 years of experience in the biotechnology industry, including business development, venture capital, program management, and research management. Prior to joining CytomX in January 2011, he was a transactional partner at Pappas Ventures, where he helped drive investments in therapeutic, medical device and molecular diagnostic companies, including the formation and financing of Afferent Pharmaceuticals, a new company developing novel pain medications based on programs licensed from Roche. Prior to Pappas Ventures, Dr. McCarthy was vice president of business development at SGX Pharmaceuticals Inc. Under his leadership, SGX entered into a wide range of strategic partnerships with major pharmaceutical companies, including a $515 million oncology alliance with Novartis and a key technology transfer alliance with Lilly. As a member of the management team, Dr. McCarthy also led a strategic re-orientation at SGX that resulted in a successful initial public offering in 2006. Prior to SGX, Dr. McCarthy was associate director of program management at Millennium Pharmaceuticals where he managed therapeutic protein programs anda research team that invented novel genomic techniques for the identification of therapeutic proteins. Dr. McCarthy is the author of 17 peer-reviewed scientific publications and is a named inventor on six issued patents and 23 filed patent applications. He received his D.Phil. in cancer biology from St. John’s College, University of Oxford; his M.B.A. from the Rady School of Management, UC San Diego; and a B.Sc. in biochemistry and pharmacology at King’s College, University of London.
______________________________________________________________________________________________
Dr. Lowman earned a B. A. in chemistry at the Johns Hopkins University, and a Ph.D. in chemistry at Purdue University, before moving to Genentech, Inc., where he spent the next 20 years in research and development of protein and antibody therapeutics. His career there began as an NIH Postdoctoral Fellow in the lab of Dr. James Wells. He then moved on to roles as scientist and senior scientist in the Protein Engineering Department, before leading Genentech’s Antibody Engineering Department as associate director and director, from 2003-2009. Most recently, he was Director of Protein Sciences at NGM Biopharmaceuticals, before joining CytomX in September 2010. His career interests include structure-based protein design, structure-function analysis, and molecular diversity techniques, which he has applied in therapeutic development projects such as human growth hormone and IGF-1, as well as to therapeutic antibodies directed against IgE, VEGF, and CD20. Dr. Lowman is an author on more than 60 scientific publications, inventor on over 60 issued patents, and editorial board member for the antibody journal mAbs.
______________________________________________________________________________________________
Debanjan Ray has more than 10 years of experience in the biotechnology industry, including strategic consulting, venture capital, and business development. Prior to joining CytomX in August of 2011, he was Vice President of Business Development at Itero Biopharmaceuticals, where he helped drive several collaborations including the company's partnership on its lead product with Watson Pharmaceuticals. Prior to Itero, Mr. Ray was an Associate Director of Business Development at Portola Pharmaceuticals. Previously, Mr. Ray was an Associate in the Life Sciences Venture Practice at J.P. Morgan Partners and a Business Analyst in the Healthcare Practice at McKinsey & Company. He received his M.B.A. from The Wharton School, University of Pennsylvania and holds a dual B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.
______________________________________________________________________________________________
Dr. West received a B.S. in Chemistry from the University of Missouri, an M.S. in Organic Chemistry from the University of Toledo, and a Ph.D. in Pharmacology from the University of Washington. As early as 1980 he used protein engineering to understand structural aspects of protein secretion, to develop molecular models for modulation of Na+ channel biology, and most recently to develop novel protein based biotherapeutics. Jim’s work in Seattle’s biotechnology community over the last 15 years has focused on therapeutic development including protein discovery and engineering, biological characterization, therapeutic validation, and included IND filings. Dr. West holds more than 15 patents covering the discovery and engineering of biologically active proteins.
